KPCB XIV Founders Fund, LLC 4
4 · Oyster Point Pharma, Inc. · Filed Nov 4, 2019
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock, par value $0.001 per share
2019-11-04+45,529→ 367,987 total - Conversion
Series A Convertible Preferred Stock
2019-11-04−45,529→ 0 total→ Common Stock, par value $0.001 per share (45,529 underlying)
Footnotes (3)
- [F1]These shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date.
- [F2]Consists of 339,284 shares of common stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV") and 28,703 shares of common stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, may be deemed to have shared voting and dispositive power over such shares.
- [F3]Consists of 41,978 shares of Series A Convertible Preferred Stock held by KPCB XIV and 3,551 shares of Series A Convertible Preferred Stock held by KPCB XIV FF. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates. Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, may be deemed to have shared voting and dispositive power over such shares.